- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00135499
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma
Study Overview
Status
Conditions
Detailed Description
In Europe, 50% or more of new non-Hodgkin lymphoma cases occur in patients older than 60 years. More than 30% are diffuse large B-cell lymphomas (DLCL).
The CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered as the standard treatment in this population. Nevertheless, this treatment is associated with some toxic events in elderly patients and it did does not succeed to increase the 3-year survival rate above 40%.
Two trials in patients above 60 years with DLCL cases were conducted by the GELA in the aim to improve the results of CHOP.
Protocol LNH 93-5 : The primary objective of this study was to compare CHOP to ACVBP in patients aged from 61 to 69 years with aggressive lymphoma and at least one adverse prognostic factor according to the International Prognostic Index.
Unlike the CHOP regimen, the ACVBP regimen includes a more intensive induction followed by a sequential consolidation with drugs different from those used during the induction phase, and includes a prevention of neuromeningeal relapses.
Out of 708 patients included in this study, the results have shown that:
- Complete response rate was the same in the two arms.
- Event free survival was significantly better in the ACVBP arm than the CHOP arm ( 5-year survival rate : 39% versus 29%, p=0.005).
- Overall survival was significantly better in the ACVBP arm than in the CHOP arm (the 5-year survival rate : 46% versus 38%, p=0.036).
- The ACVBP regimen was more toxic than the CHOP regimen, particularly in elderly patients (> 65 years) and in patients with a low performance status.
- Prevention of neuromeningeal relapses was necessary for these patients.
Protocol LNH 98-5, the objective of this study was to compare the association CHOP + rituximab (R-CHOP) to the CHOP regimen alone in elderly patients with non previously treated diffuse large B-cell lymphoma.
Long-term results based on data from 399 patients, with a median follow-up of 5 years were as follows :
- Complete response rate was better in the R-CHOP arm than in the CHOP arm (76% versus 61%, p<0.005).
- Significant prolongation of event-free survival (p<0.0002) and overall survival (p<0.0073) in the R-CHOP arm.
- No significant difference between the two arms in terms of toxicity. R-CHOP is now considered worldwide as the standard combination for these patients.
These conclusions invited us to propose a randomized trial comparing ACVBP + rituximab to CHOP + rituximab. The study population is limited to patients aged from 60 to 65 years.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Yvoir, Belgium
- Groupe d'Etude des Lymphomes de l'Adulte
-
-
-
-
-
Créteil, France, 94010
- Hopital Henri Mondor
-
Paris, France, 75010
- Hopital Saint Louis
-
Pierre-Bénite cedex, France, 69495
- Service d'Hématologie - Centre Hospitalier Lyon-Sud
-
Reims, France, 51092
- Centre Hospitalier Robert Debre
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Villejuif, France
- Institut Gustave Roussy
-
-
-
-
-
Lausanne, Switzerland
- Schweirische Arbeitsgruppe fur klinische Krebsforschung
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with diffuse large B-cell lymphoma according to the WHO classification (anti CD20 labeling)
- Aged from 60 to 65 years.
- Not previously treated.
- Ann Arbor stage II, III, IV.
- ECOG performance status 0 to 2.
- Minimum life expectancy of 3 months.
- Negative HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies test 4 weeks (except after vaccination).
- Having previously signed a written informed consent.
Exclusion Criteria:
- T-cell lymphoma.
- Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.
- Central nervous system or meningeal involvement by lymphoma.
- Contra-indication to any drug contained in the chemotherapy regimens.
- Any serious active disease (according to the investigator's decision).
- Poor renal function (creatinine level>150micromol/l), poor hepatic function (total bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
- Poor bone marrow reserve as defined by neutrophils<1.5G/l or platelets<100G/l, unless related to bone marrow infiltration.
- Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
- Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
- Adult patient under tutelage.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: R-ACVBP
Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
|
375 mg/m², D1, 4 cycles
75 mg/m², D1, 4 cycles
1200 mg/m², D1, 4 cycles
2 mg/m², D1, D5, 4 cycles
10 mg, D1, D5, 4 cycles
60 mg, D1-D5, 4 cycles
40 mg, D1-D5, 4 cycles
50 mg/m², D1, 4 cycles
750 mg/m², D1, 4 cycles
|
|
Active Comparator: R-CHOP
Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
|
375 mg/m², D1, 4 cycles
75 mg/m², D1, 4 cycles
1200 mg/m², D1, 4 cycles
60 mg, D1-D5, 4 cycles
40 mg, D1-D5, 4 cycles
50 mg/m², D1, 4 cycles
750 mg/m², D1, 4 cycles
1.4 mg/m², D1, 4 cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
event free survival
Time Frame: 8 years (end of study)
|
percentage of patients alive with no event
|
8 years (end of study)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
complete response rate
Time Frame: 8 years (end of study)
|
percentage of patients with complete response
|
8 years (end of study)
|
|
progression rate
Time Frame: 8 years (end of study)
|
percentage of patients with progression
|
8 years (end of study)
|
|
relapse rate
Time Frame: 8 years (end of study)
|
percentage of patients with relapse
|
8 years (end of study)
|
|
disease-free survival for complete responders
Time Frame: 8 years (end of study)
|
percentage of patients with complete response who remain disease-free
|
8 years (end of study)
|
|
overall survival
Time Frame: 8 years (end of study)
|
percentage of patients alive
|
8 years (end of study)
|
|
neuromeningeal relapse rate
Time Frame: 8 years (end of study)
|
percentage of patients with neuromeningeal relapse
|
8 years (end of study)
|
|
number of SAE
Time Frame: 8 years (end of study)
|
8 years (end of study)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Herve Tilly, MD, Lymphoma Study Association
Publications and helpful links
General Publications
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
- Ghesquieres H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematol Oncol. 2017 Dec;35(4):447-455. doi: 10.1002/hon.2305. Epub 2016 Jun 10.
- Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602. Epub 2015 Sep 15.
- Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. doi: 10.1182/blood-2003-02-0542. Epub 2003 Aug 14.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Rituximab
- Prednisone
- Doxorubicin
- Liposomal doxorubicin
- Vincristine
- Bleomycin
- Vindesine
Other Study ID Numbers
- LNH01-5B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.